Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).

Bartolucci J, Verdugo FJ, González PL, Larrea RE, Abarzua E, Goset C, Rojo P, Palma I, Lamich R, Pedreros PA, Valdivia G, Lopez VM, Nazzal C, Alcayaga-Miranda F, Cuenca J, Brobeck MJ, Patel AN, Figueroa FE, Khoury M. · 2017

Read Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). by Bartolucci J, Verdugo FJ, González PL, Larrea RE, Abarzua E, Goset C, Rojo P, Palma I, Lamich R, Pedreros PA, Valdivia G, Lopez VM, Nazzal C, Alcayaga-Miranda F, Cuenca J, Brobeck MJ, Patel AN, Figueroa FE, Khoury M. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6372053.txt.

Introduction

Bartolucci and co-authors present a clinical trial report in Circulation Research, the RIMECARD trial. Thirty patients with chronic heart failure and reduced ejection fraction were randomized in Chile. Half received an intravenous infusion of umbilical cord mesenchymal stem cells, and half received placebo plasma.

The authors report the infusion was feasible and safe, with no immune response against the donor cells. Treated patients showed significant gains in left ventricular function at 3, 6, and 12 months. Half of them recovered an ejection fraction above 40 percent, versus one placebo patient. Functional status and quality of life also improved. The team calls for larger trials.

Catalog record

CREATORBartolucci J, Verdugo FJ, González PL, Larrea RE, Abarzua E, Goset C, Rojo P, Palma I, Lamich R, Pedreros PA, Valdivia G, Lopez VM, Nazzal C, Alcayaga-Miranda F, Cuenca J, Brobeck MJ, Patel AN, Figueroa FE, Khoury M.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE61 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6372053

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure By Jorge Bartolucci, Fernando J. Verdugo, Paz L. González, Ricardo E. Larrea, Ema Abarzua, Carlos Goset, Pamela Rojo, Ivan Palma, Ruben Lamich, Pablo A. Pedreros, Gloria Valdivia, Valentina M. Lopez Published in: Circulation Research DOI: 10.1161/CIRCRESAHA.117.310712 ABSTRACT Supplemental Digital Content is available in the text. Stem cell therapy has been under evaluation as a treatment for heart failure (HF) with reduced ejection fraction (HFrEF) for more than a decade. Experimental studies report improvements in cardiac function and regeneration of damaged heart tissue through mechanisms, including transdifferentiation, cell fusion, and paracrine modulation.1,2 In human disease, recent reviews suggest that stem cell therapy is safe and associated with moderate clinical benefits in survival, left ventricular function, and quality of life of patients with HFrEF.3–6 Clinical trials in patients with chronic ischemic or nonischemic disease have assessed a range of cellular products and delivery routes. These include autologous or allogenic bone marrow mononuclear cells and mesenchymal stem cells (MSC), administered by intramyocardial injections, percutaneous intracoronary infusion, and exceptionally peripheral intravenous infusion.3,4,6 However, after decades of basic and clinical research, overall benefit and the best cell source and route of administration remain unsettled. Editorial, see p 1116 In This Issue, see p 1103 Meet the First Author, see p 1104 MSCs are multipotent cells with low immunogenic potential that can be isolated from adult tissues, including bone marrow, adipose tissue, and umbilical cord among other sources. The niche of origin represents an essential factor when evaluating biological differences between cell types because MSC properties can be highly influenced by microenvironmental changes.1,7 Most experimental and clinical studies have used bone marrow–derived MSC (BM-MSC), nonetheless these cells present disadvantages for clinical application, including an invasive harvesting procedure and a decreased proliferation and differentiation potential related to donor age and comorbidity.8 In contrast, umbilical cord-derived MSCs (UC-MSC) are easily attainable and expanded in vitro, have less cellular aging, and are devoid of ethical concerns. Preclinical studies have demonstrated that UC-MSC can express cardiac-specific molecules (troponin-I, connexin-43), differentiate into cardiomyocyte-like and endothelial cells in vitro, and also exert paracrine effects that enhance vascular regeneration and cardiomyocyte protection. Such actions might underlie the improvement in cardiac function observed in animal models of chronic ischemic cardiomyopathy and dilated cardiomyopathy in response to UC-MSCs.9–14 The aim of this prospective, randomized, double blinded placebo–controlled trial was to evaluate the safety and efficacy of a well-characterized source of UC-MSCs administered intravenously in patients with chronic HFrEF. METHODS Study Design and Patient Population The RIMECARD trial (Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy) was a phase 1/2, randomized, double-blind, placebo-controlled clinical trial. The study was conducted at Clínica Santa Maria and Clínica Dávila, Chile. Participants were referred from these private healthcare centers or public hospitals and randomized between December 2012 and June 2014. The experimental design was approved by the ethics committee at both participant health centers and the Chilean Metropolitan Health Service. Before enrollment, all patients agreed to participate and signed an informed consent approved by the institutional review board. This study was registered in Clinicaltrials.gov. Inclusion criteria were as follows: (1) 18 to 75 years of age, (2) chronic HFrEF with New York Heart Association (NYHA) classification I to III and left ventricular ejection fraction (LVEF) ≤40% at echocardiographic assessment, and (3) all patients had to be under optimal medical management for at least 3 months before randomization, which encompassed class I guideline-recommended therapies (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blocker, and mineralocorticoid receptor blocker) at maximal tolerable dosages. Ivabradine and sacubtril/valsartan were not included given their recent introduction in our country. Exclusion criteria were as follows: (1) End-stage HFrEF defined as patients with American College of Cardiology Foundation/American Heart Association (ACCF/AHA) stage D (candidates for specialized interventions, including heart transplantation and mechanical assistance) or terminal HF (advanced HF with poor response to all forms of treatment, frequent hospitalizations, and life expectancy <6 months). (2) Recurrent myocardial ischemia defined as any type of acute coronary syndrome 3 months before enrollment. (3) Uncontrolled ventricular tachycardia defined by sustained ventricular tachycardia, including electrical storm and incessant ventricular tachycardia with no response to antiarrhythmic medication. (4) Malignant disease with life expectancy <1 year according to tumor, node, metastasis classification. (5) Manifest ventricular asynchrony defined by intraventricular asynchrony at qualitative echocardiographic assessment (ondulating systolic movement beginning at the interventricular septum and extending to other left ventricular segments, with late activation of left ventricular lateral wall). Patients with left bundle branch block without manifest ventricular asynchrony were allowed to enroll. (6) Hematologic disease: anemia (hemoglobin ≤9.5 g/dL); leukopenia (<4000/μL); thrombocytopenia (<75 000/μL); myeloproliferative disorders, myelodysplastic syndrome, acute or chronic leukemia, and plasma cell dyscrasias (multiple myeloma, amyloidosis). (7) Recent cerebrovascular disease (<3 months). (8) Serum creatinine >2.26 mg/dL (>200 µmol/L). (9) Atrial fibrillation without optimal heart rate control in the last 3 months. Every patient assessed for eligibility was subject to coronary angiography and exercise stress test to guarantee the stability of their coronary disease and rule out signs of ischemia before inclusion into the protocol. Hence, the patients with ischemic cardiomyopathy had predominantly scar. Eligible patients were enrolled in a 1:1 randomization to intravenous infusion of UC-MSCs or placebo. The randomization list was computer generated by a person unrelated to the study. All patients were assessed at baseline and at the pre-established follow-up points of 3, 6, and 12 months. These evaluations consisted of a clinical assessment for adverse events and NYHA functional classification; Minnesota Living with Heart Failure Questionnaire (MLHFQ) and Kansas City Cardiomyopathy Questionnaire; laboratory testing including complete blood count, liver and renal function tests, brain natriuretic peptide, and high sensitivity C-reactive protein; resting ECG, signal averaged ECG, 24-hour ECG Holter monitoring; transthoracic echocardiography, cardiac magnetic resonance (CMR), and cardiopulmonary exercise test. Technical specifications on quality of life questionnaires, echocardiography, CMR, and cardiopulmonary exercise tests are provided below. Clinical researchers, study nurses, and patients were blinded to treatment allocation. Preparation, Characterization, and Infusion of UC-MSC UC-MSC treatments were processed in an ISO 9001:2015 certified good manufacturing practice type Laboratory (Cells for Cells, Santiago, Chile) under good manufacturing practice conditions according to the Food and Drug Administration Guidance for industry (current good tissue practice) and additional requirements for manufacturers of human cells, tissues, and cellular and tissue-based products. Umbilical cords were obtained from full-term human placentas by caesarean section after informed consent, from healthy donors, and were aseptically stored in sterile PBS supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin (Gibco, Gran Island). Within 3 hours of birth, the umbilical cord was sectioned and washed with PBS and antibiotics. Wharton’s jelly was dissected into small fragments (1–2 mm2 pieces), seeded in 100-mm culture plates, and maintained in Minimum Essential Medium Eagle Alpha Modifications high glucose (Gibco, Gran Island) supplemented with 10% heat-inactivated fetal bovine serum (Gibco), 1% penicillin/streptomycin, and 2 mmol/L l-glutamine (Gibco, Gran Island). At 48 hours, nonadherent cells were removed, washed with PBS, and culture medium was replaced with fresh medium every 3 days. When the cell culture reached 70% to 80% confluence, cells were detached by treatment with TrypLE TM Express (Gibco, Gran Island) and reseeded

Read the complete text